Logo for Aspect Biosystems

Meet an Unreasonable Company

Aspect Biosystems

Creating functional human tissues on demand via 3D bio-printing and tissue engineering.

Photo of Tamer Mohamed

Tamer Mohamed

Founder and CEO at Aspect Biosystems

More about Tamer »
Employees 21–50
Headquarters Vancouver, British Columbia, Canada

Aspect Biosystems is a privately held biotechnology company pioneering micro-fluidic 3D bio-printing of living human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living human tissues for medical research, therapeutic discovery, and regenerative medicine products. Their vision is a future in which drugs are developed without the use of animals, doctors know how a patient will react to a drug before prescribing it, and lifesaving transplant organs are created, not harvested. In 2018, BIOTECanada recognized Aspect as the Gold Leaf Award Winner for Emerging Company of the Year.

Currently Operating in Nine Regions

Press Mentions

June 5, 2019

Aspect Biosystems Partners with Merck, GSK, and McGill University to Enable Development of Immuno-Oncology Therapeutics

July 21, 2020

The B.C. engineer behind 3D-printed human tissues

January 9, 2020

Aspect Biosystems Raises US$20M in Series A Financing

More Companies in Health

Get the Unreasonable Newsletter

Get twice-monthly updates on Aspect Biosystems and over 300 other companies working to solve the world’s toughest problems.

Read our Privacy Policy.